Erchonia HLS for Erectile Dysfunction

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Ranjodh S. Gill, MD, FACP, Richmond, VA
Erectile Dysfunction
Erchonia HLS - Device
Eligibility
18+
Male
What conditions do you have?
Select

Study Summary

This study is to see if applying low-level laser light can provide improvement in erectile dysfunction

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 6 week

6 week
Total Erection Hardness Score
Total Score on the International Index of Erectile Function - Erectile Function

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Erchonia HLS
1 of 1
Experimental Treatment

10 Total Participants · 1 Treatment Group

Primary Treatment: Erchonia HLS · No Placebo Group · N/A

Erchonia HLS
Device
Experimental Group · 1 Intervention: Erchonia HLS · Intervention Types: Device
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Erchonia HLS
2021
N/A
~10

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 6 week
Closest Location: Ranjodh S. Gill, MD, FACP · Richmond, VA
Photo of Richmond  1Photo of Richmond  2Photo of Richmond  3
N/AFirst Recorded Clinical Trial
1 TrialsResearching Erectile Dysfunction
0 CompletedClinical Trials

Eligibility Criteria

Age 18+ · Male Participants · 8 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are in an active sexual relationship with a minimum of 2 sexual attempts per month for at least one month prior to enrollment.
You have a blood glucose level of less than or equal to 8% within one month prior to enrollment.
Testosterone level between 300 - 1000ng/dL within one month prior to enrollment.
You are male and between 40 and 80 years old.
You have been suffering from ED for at least 6 months.
You have a score of greater than or equal to 5 on the EHS.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.